Last reviewed · How we verify

Ra223 — Competitive Intelligence Brief

Ra223 (Ra223) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-emitting radiopharmaceutical. Area: Oncology.

phase 3 Alpha-emitting radiopharmaceutical Bone matrix (calcium-mimetic mechanism) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ra223 (Ra223) — European Organisation for Research and Treatment of Cancer - EORTC. Ra223 is an alpha-emitting radiopharmaceutical that targets bone metastases and delivers localized radiation to kill cancer cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ra223 TARGET Ra223 European Organisation for Research and Treatment of Cancer - EORTC phase 3 Alpha-emitting radiopharmaceutical Bone matrix (calcium-mimetic mechanism)
Dexamethasone plus Radium-223 Dexamethasone plus Radium-223 University Health Network, Toronto marketed Combination therapy: corticosteroid plus alpha-emitting radiopharmaceutical Radium-223 targets calcium-mimetic bone uptake; dexamethasone targets glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-emitting radiopharmaceutical class)

  1. European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ra223 — Competitive Intelligence Brief. https://druglandscape.com/ci/ra223. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: